Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Paying $1.53bn Upfront For Zuranolone And SAGE-324
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.